3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
Bevacizumab
119
Fluorouracil
91
Leucovorin
83
Cetuximab
83
Oxaliplatin
80
pembrolizumab
70
Irinotecan
67
Nivolumab
46
Capecitabine
43
Specimen Handling
40
regorafenib
30
Folfox protocol
29
trifluridine tipiracil drug combination
28
Magnetic Resonance Spectroscopy
27
Biopsy
27
Panitumumab
26
Standard of Care
25
HMPL-013
25
IFL protocol
21
Gemcitabine
20
Blood Specimen Collection
19
atezolizumab
18
Trifluridine
18
Cisplatin
18
tislelizumab
17
balstilimab
16
Colonoscopy
16
Carboplatin
16
encorafenib
15
Paclitaxel
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
AZD5305
×
1 year
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled